Literature DB >> 10404335

Comparative in-vitro activity of levofloxacin, other fluoroquinolones, doxycycline and erythromycin against Ureaplasma urealyticum and Mycoplasma hominis.

U Ullmann1, S Schubert, R Krausse.   

Abstract

The susceptibility of 56 Ureaplasma urealyticum and 57 Mycoplasma hominis strains to levofloxacin, ofloxacin, ciprofloxacin, fleroxacin, doxycycline and erythromycin was determined by an agar dilution method. The reference strain used was M. hominis PG 21. Agar plates containing serial dilutions of antibiotics (range 0.03-16 mg/L), and control plates (without antibiotics) were inoculated with bacteria suspended in modified Shepard's broth using a multipoint inoculator. Levofloxacin showed greater activity against all U. urealyticum and M. hominis strains compared with all other antibiotics tested. The MIC90 values for U. urealyticum were as follows: levofloxacin, 1 mg/L; ofloxacin, 2 mg/L; ciprofloxacin, 4 mg/L; fleroxacin, 4 mg/L; doxycycline, 1 mg/L; erythromycin, 8 mg/L. The MIC90s for M. hominis were: levofloxacin, 1 mg/L; ofloxacin, 2 mg/L; ciprofloxacin, 4 mg/L; fleroxacin, 4 mg/L; doxycycline, 4 mg/L; erythromycin, > or = 16 mg/L. In conclusion, the results of this study suggest that levofloxacin may be useful in the treatment of mycoplasma genital infections.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10404335     DOI: 10.1093/jac/43.suppl_3.33

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  12 in total

Review 1.  In vitro antibacterial activity and pharmacodynamics of new quinolones.

Authors:  A Dalhoff; F-J Schmitz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-04-01       Impact factor: 3.267

2.  Genital Mycoplasma infections and their resistance phenotypes in an African setting.

Authors:  L Kouegnigan Rerambiah; J-C Ndong; S Medzegue; M Elisee-Ndam; J F Djoba Siawaya
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-01-29       Impact factor: 3.267

3.  Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas.

Authors:  C M Bebear; H Renaudin; A Bryskier; C Bebear
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

Review 4.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 5.  Gatifloxacin.

Authors:  C M Perry; J A Barman Balfour; H M Lamb
Journal:  Drugs       Date:  1999-10       Impact factor: 9.546

6.  Do short-term markers of treatment efficacy predict long-term sequelae of pelvic inflammatory disease?

Authors:  Gail M Trautmann; Kevin E Kip; Holly E Richter; David E Soper; Jeffrey F Peipert; Deborah B Nelson; Wayne Trout; Dianne Schubeck; Debra C Bass; Roberta B Ness
Journal:  Am J Obstet Gynecol       Date:  2008-01       Impact factor: 8.661

7.  A case of Mycoplasma hominis meningo-encephalitis in a full-term infant: rapid recovery after start of treatment with ciprofloxacin.

Authors:  Katja C Wolthers; René F Kornelisse; Gert J J M Platenkamp; M Inge Schuurman-van der Lem; Cindy van der Schee; Nico G Hartwig; Cees M Verduin
Journal:  Eur J Pediatr       Date:  2003-05-10       Impact factor: 3.183

8.  In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.

Authors:  Ken B Waites; Donna M Crabb; Xue Bing; Lynn B Duffy
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

9.  Mycoplasma hominis necrotizing pleuropneumonia in a previously healthy adolescent.

Authors:  Andres Pascual; Marie-Helene Perez; Katia Jaton; Gaudenz Hafen; Stefano Di Bernardo; Jacques Cotting; Gilbert Greub; Bernard Vaudaux
Journal:  BMC Infect Dis       Date:  2010-11-24       Impact factor: 3.090

10.  Ureaplasma serovars & their antimicrobial susceptibility in patients of infertility & genital tract infections.

Authors:  Benu Dhawan; Neena Malhotra; Vishnubhatla Sreenivas; Jyoti Rawre; Neena Khanna; Rama Chaudhry; Suneeta Mittal
Journal:  Indian J Med Res       Date:  2012-12       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.